Results 191 to 200 of about 115,328 (341)
Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis. [PDF]
Jin H +9 more
europepmc +1 more source
Periodontal Disease as a Risk Factor for Bisphosphonate‐Related Osteonecrosis of the Jaw
Vivek Thumbigere‐Math +6 more
openalex +2 more sources
Orthodontic treatment in periodontitis patients
Abstract This paper examines the complex interplay between orthodontic intervention and periodontal conditions in individuals with periodontitis. It outlines diagnostic and treatment approaches for adolescents and adults, considering their distinct periodontal, dental, and behavioral needs.
Tali Chackartchi +3 more
wiley +1 more source
Bisphosphonates as a Tacrolimus-Sparing Strategy in Kidney Transplantation: Insights from a Retrospective Analysis. [PDF]
Koh HB +12 more
europepmc +1 more source
Abstract Peri‐implant diseases are dysbiosis‐mediated inflammatory disorders that occur in susceptible hosts. Antimicrobials and immunomodulatory agents therefore might be pertinent as adjunctive measures in the treatment of such disorders. The aim of this narrative review was to examine the existing evidence and assess the effectiveness of emerging ...
Alberto Monje +3 more
wiley +1 more source
Bisphosphonates in hormone-sensitive metastatic prostate cancer: do they still matter? [PDF]
Shakil S, Ijaz M, Shah AK.
europepmc +1 more source
The Role of Bisphosphonates in Early Breast Cancer [PDF]
Alexander Paterson
openalex +1 more source
Revision Distal Bicep Repair in the Setting of Heterotopic Ossification: Case Study
Radiographic and intraoperative findings demonstrating heterotopic ossification following distal biceps tendon repair. ABSTRACT Heterotopic ossification (HO) following distal biceps tendon repair is an uncommon but potential complication. This may present pain, limited range of motion, or sensory changes due to nerve compression.
Aidan M. Brikho +2 more
wiley +1 more source
Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
What's new? Although human epidermal growth factor 2‐positive (HER2+) breast cancer is an aggressive malignancy, significant survival benefits are possible with targeted anti‐HER2 therapies. Whether these therapies are used as recommended, however, is unknown. Here, the authors investigated data from population‐based registries in Norway to assess anti‐
Kathrine F. Vandraas +9 more
wiley +1 more source

